tirzepatide blood in urine reduces albuminuria among adults with type 2 diabetes SURPASS trials Tirzepatide and Cardiovascular Outcomes: A

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss but cause gastrointestinal side effects, affecting adherence

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds.

Whether opting for monthly, quarterly, or weekly injections, patients can choose a plan that aligns with their weight loss goals and financial preferences

Yet the responses circulating in mainstream spaces are often reductivelike just take this drug or ditch the carbsmissing the individual context, lived experience, and long-term sustainability that real health conversations deserve.Thats exactly why Ive written this a

Whether these translate into meaningful extensions of healthspanor ultimately lifespanremains one of the biggest unanswered questions in medicine

Therefore, although DPP-4 inhibitors have attractive clinical features, the benefits that might be expected from GLP-1 signaling may be undermined by their actions to enhance SDF-1.